Remove tag competition
article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

Since that time, Biogen’s MS drugs have faced intense competition as MS patients continue to vent on social media that the Biogen drug has nasty side effects. If the drug is approved you can bet that it’s going to carry a huge price tag. Will they follow the science or will they put a price tag on hope?

Drugs 187
article thumbnail

Walmart Introduces bettergoods, a New Private Label Brand

XTalks

Competition from Other Retailer Brands The introduction of bettergoods positions Walmart in direct competition with other major retailers’ private labels, such as Target’s Good & Gather and Kroger’s Simple Truth. Photo courtesy of Walmart.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds August 4, 2023: AI & ML: Want to Play a Game? (Eric Perakslis, PhD)

Rethinking Clinical Trials

They use motivation, game design, competition, curiosity, collaboration, challenges, media, and learning to accomplish something. Tags #pctGR, @Collaboratory1 The post Grand Rounds August 4, 2023: AI & ML: Want to Play a Game? “Serious games” are games designed for a purpose beyond pure entertainment.

article thumbnail

Establishing Safer Food Supply Chains with Blockchain and IoT

XTalks

Implementing these technologies would require investing in handheld computers and tablets, barcode label printers and scanners, and special labels and tags. Food and beverage companies that invest in these technologies will have a competitive advantage by being able to meet consumers’ growing expectations for safe and traceable food.

article thumbnail

ASH: Argenx cues up a second use for efgartigimod

pharmaphorum

Vyvgart is already approved to treat generalised myasthenia gravis, getting a green light for that indication from the FDA a year ago, and launched with a $225,000 per annum price tag in competition with rival gMG drugs like AstraZeneca/Alexion’s C5 inhibitor Soliris (eculizumab).

Sales 52
article thumbnail

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

pharmaphorum

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen are closing in after the FDA accepted a filing for their cut-price rival.

article thumbnail

With rivals threatening, Argenx scores key myasthenia gravis win

pharmaphorum

Vyvgart (efgartigimod alfa) became the first drug in the FcRn class to be approved by the FDA last December, and despite a $225,000 annual price tag is predicted to make relatively modest sales in its IV version, which will compete with other IV gMG drugs like AstraZeneca/Alexion’s C5 inhibitor Soliris (eculizumab).